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Abstract
Background:  Pro-arrhythmic concerns with most anti-arrhythmic agents in patients with 
significant left ventricular hypertrophy (LVH) limits options when anti-arrhythmic therapy is 
indicated. Ranolazine, an anti-anginal agent which inhibits late Na+ currents, indirectly causes a 
decrease in diastolic cardiomyocyte Ca++ levels producing an energy sparing effect. Ranolazine 
also inhibits triggered activity in animal studies and has anti-arrhythmic properties in patients 
with ischemic heart disease. Here we report the dramatic anti-arrhythmic effects of ranolazine in 
a patient with frequent ventricular and supraventricular ectopy in the setting of hypertrophic 
heart disease without significant coronary artery disease.                                                           
Methods:  A 72 year old hypertensive patient with palpitations  and significant exercise 
intolerance due to dyspnea was evaluated with echocardiography, thallium stress testing and 
cardiac catheterization. Holter monitor data prior to, and after institution of ranolazine 1000 mg 
twice daily was compared. Patient tolerance and sense of well being after ranolazine was 
assessed.  
Results: Significant LVH was noted and obstructive coronary artery disease was ruled out by 
cardiac catheterization. Within two hours of the initial dose of ranolazine a marked decrease in 
ventricular ectopy was observed. Ventricular ectopy on Holter monitor decreased approximately 
12 fold (23.8% of beats to1.9%) while supraventricular ectopy decreased approximately 7 fold 
(5.3% of beats to 0.8%). The decrease in ectopy was associated with an improved sense of well 
being.  
Conclusion: Ranolazine had rapid onset, potent anti-arrhythmic properties in the absence of 
obstructive coronary artery disease in a patient with LVH and may be an ideal agent in patients 
where few anti-arrhythmic options exist.                                                                                       
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Introduction  
Malignant arrhythmias are a leading cause of morbidity and mortality in patients with, and 
without, ischemic heart disease [1-7]. In patients with left ventricular hypertrophy due to 
hypertension, ventricular arrhythmias are common and associated with an increased risk of 
sudden cardiac death in excess of the risk attributable to hypertension alone or presence of 
coronary artery disease [2-4]. The mechanisms of arrhythmias are varied and include enhanced 
automaticity, reentry and triggered activity from after depolarizations [5-10]. Triggered activity 
may be the most important mechanism in patients without cardiac ischemia [5-10].                  
Ranolazine is a novel anti-anginal agent, which inhibits the abnormal late inward Na+ current in 
ventricular   cardiomyocytes   [11].   This   produces   an   energy-sparing   effect   and   indirectly 
decreases diastolic intracellular cardiomyocyte Ca++ levels. This effect also improves membrane 
stability [11]. Ranolazine has also been shown to be a potent inhibitor of after depolarizations 
produced by a number of mechanisms [12-14]. As such, it could prove to have potent anti-
arrhythmic properties in some arrhythmic situations, particularly those mediated by after-
depolarizations. Additionally  ranolazine inhibits  IKr and prolongs repolarization  without 
increasing the dispersion of repolarization [12-14].                                                                     
In this case report, we describe the dramatic anti-arrhythmic effects of ranolazine in a patient 
with   significant   left   ventricular   hypertrophy   and   symptomatic   ventricular   ectopy   and 
supraventricular   ectopy.                                                                            
Case   Report                                                                                  
A 72-year-old male presented to our office for evaluation of a one- month history of increasing 
exertional dyspnea, palpitations and fatigue. The patient had past history of hypertension, 
ulcerative colitis with mild associated anemia, prostate cancer, and mild sinus bradycardia. His 
medications included furosemide 20mg/day and amlodipine 5mg/day. His physical exam was 
unremarkable except for mild bradycardia (55 beats/min.), frequent ectopic beats and a soft 
systolic ejection murmur.                                                                                             
Initial workup included a normal chest x-ray, electrolytes, renal indices, and thyroid function 
studies. A hemogram confirmed his past history of mild anemia (hemoglobin 12.7 grams/dl) 
with a normal differential counts. The electrocardiogram revealed mild sinus bradycardia with 
frequent premature ventricular contractions (PVCs), non-specific ST-T wave changes and a 
corrected QT interval of 471 msec (Figure 1).
Figure 1: Electrocardiogram showing LVH and frequent ventricular ectopy. 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 11 (3): 84-88 (2011)Murdock DK, “Suppression of ventricular ectopy with ranolazine”                                       86
Transthoracic echocardiogram revealed concentric left ventricular hypertrophy (posterior wall 
thickness 15 mm, septal thickness 18 mm) without any out flow obstruction, left atrial 
enlargement, and grade II diastolic dysfunction. During the stress test, the patient was unable to 
tolerate exercise due to severe dyspnea and reached a heart rate of only 116 beats/min. 
Consequently the study was completed using an adenosine stress agent. Prior to terminating the 
exercise, moderate diffuse ST segment depression was observed in the inferior and anterior 
leads. His baseline electrocardiogram revealed frequent PVCs in a pattern of bigeminy. The 
PVCs decreased in frequency with exercise. The Thallium imaging was negative for ischemia 
and the ejection fraction was estimated at 66%.                                                                         
24-hour Holter monitoring revealed frequent PVCs (Table 1). Ventricular ectopic beats made 
up for 23.8% of total beats. There were triplets and couplets present, but no runs of ventricular 
tachycardia. There was moderately frequent supraventricular ectopy as well accounting for 
5.3% of total beats. There was a tendency towards bradycardia.
Table 1: Effect of ranolazine on Holter data
PAC's: premature atrial contractions, PVC's: premature ventricular contractions 
Because of his symptoms, frequent ectopy and concerns for "balanced ischemia" he underwent 
cardiac catheterization which revealed very mild non-obstructive coronary artery disease and a 
normal global left ventricular systolic function. The left ventricular end-diastolic pressure was 
elevated at 30 mm Hg. During the monitoring period prior to, and during the catheterization, the 
patient continued to demonstrate very frequent ventricular ectopy.                                
On the basis of the information obtained, the patient was felt to have hypertensive heart disease 
with the frequent ectopic beats impairing cardiac performance. We felt it was highly likely that 
triggered activity was the mechanism of his ectopy. Thus, shortly after the catheterization he 
was given a 2000 mg dose of ranolazine [15] as he recovered from the catheterization in a 
monitored setting. Within two hours of this dose, a marked reduction in ectopy frequency was 
observed and consequently he was discharged on a ranolazine dose of 1,000mg twice daily. A 
follow-up Holter monitor was arranged which revealed a dramatic reduction in ventricular and 
supraventricular ectopic activity (Table 1).   A slight reduction in average heart rate was 
observed without a decrease in minimum heart rate or increase in the longest R to R interval 
(Table 1). A repeat ECG showed absence of all ectopy and a corrected QT interval of 443 
msec.  
The patient noted marked improvement of his presenting symptoms and consequently requested 
that we continue ranolazine, though the dose was later lowered to 1000 mg in the morning and 
500 mg in the evening because of constipation.                                                                           
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Discussion
In our patient with frequent symptomatic ectopy and significant left ventricular hypertrophy due 
to chronic hypertension, we observed a rapid and marked reduction in both ventricular and 
supraventricular ectopy with the anti-anginal agent ranolazine. Indeed within a couple of hours 
the ectopy went from being extremely frequent to very occasional. This occurred despite the 
absence   of   obstructive   coronary   artery   disease   indicating   that   this   was   a   direct 
electrophysiologic effect of this medication. We have previously reported the ability of 
ranolazine to favorable effect ventricular ectopy in a case on non-ischemic cardiomyopathy in a 
rapid manner [16] as well idiopathic ventricular tachycardia in a patient without structural heart 
disease [17]. This case extends these observations to the setting of hypertensive heart disease 
complicated by significant left ventricular hypertrophy.                                             
In patients with significant left ventricular hypertrophy, there are limited anti-arrhythmic 
options due to the risk of pro-arrhythmia [18]. Most anti-arrhythmic agents induce QT 
prolongation and increase the dispersion of repolarization, an effect worsened by the presence 
of left ventricular hypertrophy [19]. Ranolazine has minimal effects on the QT interval and does 
not increase dispersion of repolarization [13]. Ranolazine has no known pro-arrhythmic effects 
and consequently may be the ideal agent in such circumstances.                                    
Although we feel that a reduction in triggered activity most likely explained the reduction in 
ectopy [12-14], we can not be certain as to the mechanism involved. In addition to decreasing 
triggered activity, therapeutic levels of ranolazine also inhibits IKr which slightly prolongs 
repolarization and decreases dispersion of repolarization [12-14]. These effects could make re-
entry harder to become initiated or sustained.                                                                         
Our patient also had relative bradycardia, likely reflecting sinus node dysfunction. This 
precluded us from initially trying a beta blocker for the ectopy.  Although we observed a slight 
decrease in the average heart rate with ranolazine between the two Holter monitors, no pauses 
or worsening of the minimum heart rate was observed.                                                             
Summary
Ranolazine was remarkably effective in decreasing ventricular and supraventricular ectopy in a 
patient with significant hypertrophic heart disease secondary to chronic hypertension. More 
investigations   into   the   anti-arrhythmic   effects   of   this   agent   in   man   are   warranted.
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